10-Q: Omada Health Sees Strong Revenue Growth, Margin Expansion

Omada Health reported a 43% increase in total revenue for the second quarter of 2026 compared to the same period in 2025, driven by member growth and program expansion, alongside improved gross margins.

Summary

• Omada Health reported a 43% increase in total revenue for the three months ended June 30, 2026, reaching $87.8 million, compared to $61.4 million in the same period of 2025.
• For the six months ended June 30, 2026, total revenue increased by 43% to $165.9 million from $116.3 million in the prior year.
• Gross profit saw a significant increase of 58% to $63.8 million for the three-month period, with gross margin expanding to 73% from 66% year-over-year.
• Operating expenses increased across R&D, Sales & Marketing, and G&A, reflecting investments in growth and public company operations.
• The company reported a net income of $5.3 million for the three months ended June 30, 2026, a significant improvement from a net loss of $5.3 million in the prior year.
• However, the company still has an accumulated deficit of $454.4 million as of June 30, 2026.
• Cash and cash equivalents stood at $221.7 million as of June 30, 2026.
• The company identified a material weakness in internal control over financial reporting related to formalized processes and control activities for financial close and reporting.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with significant revenue growth and improved gross margins, although the company continues to operate at a net loss.

Positives

• Total revenue increased by 43% to $87.8 million for the three months ended June 30, 2026, compared to $61.4 million in the same period of 2025.
• Hardware revenue saw a substantial increase of 62% to $7.1 million for the three months ended June 30, 2026.
• Gross profit increased by 58% to $63.8 million for the three months ended June 30, 2026.
• Gross margin improved by 7 percentage points to 73% for the three months ended June 30, 2026, compared to 66% in the prior year.
• The company achieved net income of $5.3 million for the three months ended June 30, 2026, a significant turnaround from a net loss in the prior year.
• Interest expense decreased by 99% due to extinguishment of financing arrangements.
• Interest income increased by 104% driven by higher cash balances from IPO proceeds.

Negatives

• The company continues to have an accumulated deficit of $454.4 million as of June 30, 2026.
• Operating expenses increased across all categories (R&D, Sales & Marketing, G&A) compared to the prior year.
• Despite net income in the current quarter, the company has a history of net losses and may not achieve consistent profitability.
• A material weakness in internal control over financial reporting was identified, related to inadequate formalized processes and control activities for financial close and reporting.

Risks

• The company has a limited operating history and has grown significantly, facing challenges in managing this growth effectively.
• Failure to achieve and maintain market acceptance for its programs could lead to sales below expectations.
• The market for virtual care is new, rapidly evolving, and increasingly competitive.
• Reliance on a limited number of customers and channel partners, particularly affiliates of The Cigna Group, poses a concentration risk.
• The company's revenue depends on member engagement and the achievement of clinical outcomes and cost savings, with potential for fee repayments if targets are not met.
• Cybersecurity incidents, data breaches, and other IT system disruptions could materially disrupt operations and compromise confidential information.
• Changes in healthcare regulations or reductions in government spending could negatively impact the business.
• The company has identified a material weakness in internal control over financial reporting, which could affect investor confidence if not effectively remediated.

Future Outlook

The company expects to continue investing in its core business and areas that enhance its platform, programs, or operations. It believes its current cash position is sufficient for at least the next 12 months, but future capital requirements will depend on growth rate, R&D and sales/marketing expenditures, market acceptance, and potential acquisitions.

Management Comments

• "Our mission is to bend the curve. Our hope is that, one day, tomorrows epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada."
• "As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms."
• "We believe Omada is well positioned to support customers across a range of coverage strategies: for those that cover GLP1s, our GLP1 companion programs are designed to help enhance medication effectiveness and durability; for those that do not, our proven prevention and weight health program, together with our broader cardiometabolic offerings, provides an evidencebased path to improving weight and metabolic health without relying on expensive drugs."

Industry Context

StockSavvy.ai notes that Omada Health's performance aligns with broader trends in the digital health sector, particularly the increasing demand for chronic condition management and the growing interest in GLP-1 therapies. The company's ability to cater to both employers covering GLP-1s and those seeking alternatives positions it well in a dynamic market.

Legal Proceedings

• The company is not presently a party to any litigation that, if determined adversely, would have a material adverse effect on its business, operating results, cash flows, or financial condition.

Related Party Transactions

• Significant amounts are included in accounts receivable, revenue, cost of revenue, operating expenses, and deferred revenue from related parties, primarily affiliates of The Cigna Group.

Stakeholder Impact

• Shareholders may see potential for increased value due to revenue growth and margin improvement, but the ongoing accumulated deficit and material weakness in controls present risks.
• Employees may benefit from the company's growth and investment in personnel, but face risks associated with the company's overall financial performance and internal control environment.
• Customers and channel partners benefit from Omada's expanding virtual care offerings, with potential for improved health outcomes and cost savings, but are also exposed to the company's operational and financial stability.
• Suppliers may see increased business due to higher member enrollment and device fulfillment, but are subject to the company's payment terms and overall financial health.

Next Steps

• Continue investing in platform, programs, and operations.
• Focus on acquiring new customers and channel partners.
• Drive program expansion within the existing customer base.
• Enhance member enrollment and engagement strategies.
• Continue to monitor and adapt to evolving healthcare regulations and market trends.
• Remediate the identified material weakness in internal control over financial reporting.

Key Dates

Recommendation

While the company shows strong top-line growth and improved margins, the continued accumulated deficit, the identified material weakness in internal controls, and the competitive landscape warrant a cautious 'hold' rating. Further progress in profitability and control remediation is needed to justify a 'buy' recommendation.

Keywords

digital health, virtual care, cardiometabolic programs, diabetes prevention, hypertension, musculoskeletal conditions, GLP-1, health coaching